Pfizer to stop the genetic therapy for hemophilia b
(MedPage Today) – After less than a year of approval, Pfizer said it plans to stop the genetic therapy of the hemophilia b Vianoccoin Ilafovic (beqvez) in all global markets, indicating poor demand. “Pfizer made the decision to stop …